drugset / Trial / NCT00947882

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882

Phase 2 Completed 404 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Timeline

Start
2009-08
Primary completion
2011-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 10 mg
Subject Degarelix Other / unclassified 20 mg
Subject Degarelix Other / unclassified 30 mg

Indications

No indication recorded.